Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Fu, Rong ^a   Gao, Shan ^a   Peng, Fengping ^a   Li, Jing ^a   Liu, Hui ^a   Wang, Huaquan ^a   Xing, Linmin ^a   Shao, Zonghong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Cellular immunity; Multiple myeloma; Osteoblast

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BORTEZOMIB; CALCIUM; INTERLEUKIN 7; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; MALE; MULTIPLE MYELOMA; OSTEOBLAST; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE;

EID: 84906834765     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-14-62     Document Type: Article

References (18)

1. Lentzsch S, Ehrlich LA, Roodman GD. Pathophysiology of multiple myeloma bone disease. Hematol Oncol Clin North Am 2007, 21:1035-1049. 10.1016/j.hoc.2007.08.009, 17996587.
2. Terpos E, Sezer O, Croucher P. Myeloma bone disease and proteasome inhibition therapies. Blood 2007, 110:1098-1104. 10.1182/blood-2007-03-067710, 17494860.
3. Noonan K, Borrello I. The immune microenvironment o f myeloma. Cancer Microenviron 2011, 4:313-323. 10.1007/s12307-011-0086-3, 3234331, 21866321.
4. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008, 29:403-440. 10.1210/er.2007-0038, 2528852, 18451259.
5. Beloti MM, Rosa AL. Osteoblast differentiation of human BM cells under continuous and discontinuous treatment with dexamethasone. Braz Dent J 2005, 16:156-161.
6. Harbers GM, Healy KE. The effect of ligand type and density on osteoblast adhesion, proliferation, and matrix mineralization. J Biomed Mater Res A 2005, 75:855-869.
7. Pinzone JJ, Hall BM, Thudi NK. The role of dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113:517-525. 10.1182/blood-2008-03-145169, 2628360, 18687985.
8. Qiang YW, Shaughnessy JD, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008, 15:374-382.
9. Medinger M, Fischer N, Tzankov A. Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol 2010, 729725. doi:10.1155/2012/753407.
10. Danylesko I, Beider K. Avichai shimoni. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol 2012, 2012:797165. doi:10.1155/2012/797165, 3546469, 23346187.
11. Sakaguchi S. Regulatory T, cells: key controllers of immunologic selftolerance. Cell 2000, 101:455-458. 10.1016/S0092-8674(00)80856-9, 10850488.
12. Brygida B, John C, Jeremy L, Jeffrey A. Bluestone and Kevan C. Herold. TCR stimulation with modified anti-CD3 mAb expands CD8 + T cell population and induces CD8 + CD25 + Tregs. J Clin Invest 2005, 115:2904-2913. 10.1172/JCI23961, 1201661, 16167085.
13. Li H, Hong S, Qian J. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4 and CD8 T cells. Blood 2010, 116:210-217. 10.1182/blood-2009-11-255026, 2910608, 20304810.
14. Bikker A, Kruize AA, van der Wurff-Jacobs KM, Peters RP, Kleinjan M, Redegeld F, de Jager W, Lafeber FP, van Roon JA. Interleukin-7 and toll-like receptor 7 induce synergistic B cell and T cell activation. Plos One 2014, 9(4):e94756. 10.1371/journal.pone.0094756, 3989236, 24740301.
15. Castella B, Riganti C, Fiore F. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβCD8 + T cells, regulatory T cells, and dendritic cells. J Immunol 2011, 187:1578-1590. 10.4049/jimmunol.1002514, 21753152.
16. Roodman GD. Bone building with bortezomib. J Clin Invest 2008, 118:462-464. 2213378, 18219395.
17. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A, Rizzoli V. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007, 110(1):334-338. 10.1182/blood-2006-11-059188, 17371942.
18. Mohty M, Malard F, Mohty B, Savani B, Moreau P, Terpos E. The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer 2014, 120(5):618-623. 10.1002/cncr.28481, 24249482.